Neutralizing antibodies after infection with dengue 1 virus.

PubWeight™: 1.33‹?› | Rank: Top 10%

🔗 View Article (PMC 2725871)

Published in Emerg Infect Dis on February 01, 2007

Authors

Maria G Guzman1, Mayling Alvarez, Rosmari Rodriguez-Roche, Lidice Bernardo, Tibaire Montes, Susana Vazquez, Luis Morier, Angel Alvarez, Ernest A Gould, Gustavo Kouri, Scott B Halstead

Author Affiliations

1: "Pedro Kouri" Tropical Medicine Institute, Havana, Cuba. lupe@ipk.sld.cu

Articles citing this

Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II. J Virol (2008) 2.39

Dynamics of dengue disease severity determined by the interplay between viral genetics and serotype-specific immunity. Sci Transl Med (2011) 2.29

Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus. Nat Immunol (2016) 2.08

Interactions between serotypes of dengue highlight epidemiological impact of cross-immunity. J R Soc Interface (2013) 1.75

Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens. PLoS One (2009) 1.72

Role of dendritic cells in antibody-dependent enhancement of dengue virus infection. J Virol (2008) 1.65

Dengue viruses - an overview. Infect Ecol Epidemiol (2013) 1.40

A shorter time interval between first and second dengue infections is associated with protection from clinical illness in a school-based cohort in Thailand. J Infect Dis (2013) 1.33

Antibodies play a greater role than immune cells in heterologous protection against secondary dengue virus infection in a mouse model. Virology (2008) 1.24

Inferring the serotype associated with dengue virus infections on the basis of pre- and postinfection neutralizing antibody titers. J Infect Dis (2010) 1.24

Dengue viruses cluster antigenically but not as discrete serotypes. Science (2015) 1.12

Rational design of a live attenuated dengue vaccine: 2'-o-methyltransferase mutants are highly attenuated and immunogenic in mice and macaques. PLoS Pathog (2013) 1.11

New insights into the immunopathology and control of dengue virus infection. Nat Rev Immunol (2015) 1.10

Understanding the dengue viruses and progress towards their control. Biomed Res Int (2013) 1.02

The complexity of antibody-dependent enhancement of dengue virus infection. Viruses (2010) 0.99

Analysis of cross-reactive antibodies recognizing the fusion loop of envelope protein and correlation with neutralizing antibody titers in Nicaraguan dengue cases. PLoS Negl Trop Dis (2013) 0.98

CD8+ T Cells Can Mediate Short-Term Protection against Heterotypic Dengue Virus Reinfection in Mice. J Virol (2015) 0.97

Dengue virus neutralizing antibody levels associated with protection from infection in thai cluster studies. PLoS Negl Trop Dis (2014) 0.93

Heterologous Protection against Asian Zika Virus Challenge in Rhesus Macaques. PLoS Negl Trop Dis (2016) 0.91

Neutralizing antibody titers against dengue virus correlate with protection from symptomatic infection in a longitudinal cohort. Proc Natl Acad Sci U S A (2016) 0.90

Incidence and seroprevalence of dengue virus infections in Australian travellers to Asia. Eur J Clin Microbiol Infect Dis (2011) 0.90

Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies. J Virol (2015) 0.87

Analysis of human monoclonal antibodies generated by dengue virus-specific memory B cells. Viral Immunol (2012) 0.84

Specific genetic markers for detecting subtypes of dengue virus serotype-2 in isolates from the states of Oaxaca and Veracruz, Mexico. BMC Microbiol (2008) 0.83

Activation of TLR2 and TLR6 by Dengue NS1 Protein and Its Implications in the Immunopathogenesis of Dengue Virus Infection. PLoS Pathog (2015) 0.82

Increased replicative fitness of a dengue virus 2 clade in native mosquitoes: potential contribution to a clade replacement event in Nicaragua. J Virol (2014) 0.81

Dengue Virus (DENV) Neutralizing Antibody Kinetics in Children After Symptomatic Primary and Postprimary DENV Infection. J Infect Dis (2015) 0.79

Serological evidence for transmission of multiple dengue virus serotypes in Papua New Guinea and West Papua prior to 1963. PLoS Negl Trop Dis (2017) 0.75

Choroidal neovascularization induced by immunogenic alteration of the retinal pigment epithelium in dengue Fever. Case Rep Ophthalmol (2015) 0.75

An Approach for a Synthetic CTL Vaccine Design against Zika Flavivirus Using Class I and Class II Epitopes Identified by Computer Modeling. Front Immunol (2017) 0.75

Analysis of Individuals from a Dengue-Endemic Region Helps Define the Footprint and Repertoire of Antibodies Targeting Dengue Virus 3 Type-Specific Epitopes. MBio (2017) 0.75

Articles cited by this

Research on dengue during World War II. Am J Trop Med Hyg (1952) 8.76

A plaque reduction test for dengue virus neutralizing antibodies. J Immunol (1967) 5.78

Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am J Trop Med Hyg (1989) 4.79

Dengue virus structural differences that correlate with pathogenesis. J Virol (1999) 4.26

Failure of secondary infection with American genotype dengue 2 to cause dengue haemorrhagic fever. Lancet (1999) 3.97

Epidemiologic studies on Dengue in Santiago de Cuba, 1997. Am J Epidemiol (2000) 3.70

Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. J Infect Dis (2004) 3.68

Dengue hemorrhagic fever in Cuba, 1981: a retrospective seroepidemiologic study. Am J Trop Med Hyg (1990) 3.41

Effect of dengue-1 antibodies on American dengue-2 viral infection and dengue haemorrhagic fever. Lancet (2002) 2.56

Simplified plaque reduction neutralization assay for dengue viruses by semimicro methods in BHK-21 cells: comparison of the BHK suspension test with standard plaque reduction neutralization. J Clin Microbiol (1985) 2.31

Serological diagnosis of dengue by an ELISA inhibition method (EIM). Mem Inst Oswaldo Cruz (1992) 2.12

Hemorrhagic dengue in Cuba: history of an epidemic. Bull Pan Am Health Organ (1986) 2.07

Enhanced severity of secondary dengue-2 infections: death rates in 1981 and 1997 Cuban outbreaks. Rev Panam Salud Publica (2002) 1.75

Fatal dengue hemorrhagic fever in Cuba, 1997. Int J Infect Dis (1999) 1.55

Cross-serotype neutralization of dengue virus in Aotus nancymae monkeys. J Infect Dis (2005) 1.43

Reemergence of dengue in Cuba: a 1997 epidemic in Santiago de Cuba. Emerg Infect Dis (1998) 1.38

Partial nucleotide and amino acid sequences of the envelope and the envelope/nonstructural protein-1 gene junction of four dengue-2 virus strains isolated during the 1981 Cuban epidemic. Am J Trop Med Hyg (1995) 1.36

Detection and genetic relationship of dengue virus sequences in seventeen-year-old paraffin-embedded samples from Cuba. Am J Trop Med Hyg (1999) 1.07

Dengue haemorrhagic fever in Cuba. II. Clinical investigations. Trans R Soc Trop Med Hyg (1984) 1.02

[Epidemiology of dengue and hemorrhagic dengue in Santiago, Cuba 1997]. Rev Panam Salud Publica (1999) 0.98

Sequential infection as risk factor for dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS) during the 1981 dengue hemorrhagic Cuban epidemic. Mem Inst Oswaldo Cruz (1993) 0.93

Dengue virus type 2 in Cuba, 1997: conservation of E gene sequence in isolates obtained at different times during the epidemic. Arch Virol (2004) 0.90

[Survey of dengue in Cuba. 1978-1979]. Rev Cubana Med Trop (1982) 0.90

Dengue haemorrhagic fever in Cuba. I. Serological confirmation of clinical diagnosis. Trans R Soc Trop Med Hyg (1984) 0.84

[Direct sequencing of an amplified product from a serum sample]. Rev Cubana Med Trop (1996) 0.79

Articles by these authors

Dengue: a continuing global threat. Nat Rev Microbiol (2010) 9.96

Effect of age on outcome of secondary dengue 2 infections. Int J Infect Dis (2002) 3.77

Cost of dengue cases in eight countries in the Americas and Asia: a prospective study. Am J Trop Med Hyg (2009) 3.42

Chikungunya virus adapts to tiger mosquito via evolutionary convergence: a sign of things to come? Virol J (2008) 3.39

Live flavivirus vaccines: reasons for caution. Lancet (2004) 3.36

Evaluation of diagnostic tests: dengue. Nat Rev Microbiol (2010) 2.91

Dengue and dengue hemorrhagic fever in the Americas: lessons and challenges. J Clin Virol (2003) 2.90

Phylogenetic relationships and differential selection pressures among genotypes of dengue-2 virus. Virology (2002) 2.75

Effect of dengue-1 antibodies on American dengue-2 viral infection and dengue haemorrhagic fever. Lancet (2002) 2.56

Best practices in dengue surveillance: a report from the Asia-Pacific and Americas Dengue Prevention Boards. PLoS Negl Trop Dis (2010) 2.45

Phylogenetic analysis reveals a low rate of homologous recombination in negative-sense RNA viruses. J Gen Virol (2003) 2.43

Dengue hemorrhagic fever in infants: a study of clinical and cytokine profiles. J Infect Dis (2004) 2.43

Multi-country evaluation of the sensitivity and specificity of two commercially-available NS1 ELISA assays for dengue diagnosis. PLoS Negl Trop Dis (2010) 2.33

Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. Arch Virol (2013) 2.29

Evaluation of commercially available anti-dengue virus immunoglobulin M tests. Emerg Infect Dis (2009) 2.26

Serological evidence of West Nile virus, Usutu virus and Sindbis virus infection of birds in the UK. J Gen Virol (2003) 2.17

Genetic characterization of tick-borne flaviviruses: new insights into evolution, pathogenetic determinants and taxonomy. Virology (2006) 2.01

Complete genome analysis and molecular characterization of Usutu virus that emerged in Austria in 2001: comparison with the South African strain SAAR-1776 and other flaviviruses. Virology (2004) 1.98

Structure and functionality in flavivirus NS-proteins: perspectives for drug design. Antiviral Res (2009) 1.87

Chikungunya fever: epidemiology, clinical syndrome, pathogenesis and therapy. Antiviral Res (2013) 1.85

Effect of single dose of SA 14-14-2 vaccine 1 year after immunisation in Nepalese children with Japanese encephalitis: a case-control study. Lancet (2005) 1.84

Cost-effectiveness of a pediatric dengue vaccine. Vaccine (2004) 1.83

Enhanced severity of secondary dengue-2 infections: death rates in 1981 and 1997 Cuban outbreaks. Rev Panam Salud Publica (2002) 1.75

Natural history of dengue virus (DENV)-1 and DENV-4 infections: reanalysis of classic studies. J Infect Dis (2007) 1.74

Single dose of SA 14-14-2 vaccine provides long-term protection against Japanese encephalitis: a case-control study in Nepalese children 5 years after immunization. drjbtandan@yahoo.com. Vaccine (2007) 1.63

IL-10 levels in Dengue patients: some findings from the exceptional epidemiological conditions in Cuba. J Med Virol (2004) 1.50

Tick cell lines: tools for tick and tick-borne disease research. Trends Parasitol (2007) 1.48

Dengue hemorrhagic Fever caused by sequential dengue 1-3 virus infections over a long time interval: Havana epidemic, 2001-2002. Am J Trop Med Hyg (2006) 1.45

Potential risks associated with the proposed widespread use of Tamiflu. Environ Health Perspect (2007) 1.39

Reappearance of chikungunya, formerly called dengue, in the Americas. Emerg Infect Dis (2015) 1.37

Tick-borne flaviviruses. Adv Virus Res (2003) 1.36

Molecular evolution of the insect-specific flaviviruses. J Gen Virol (2011) 1.34

Association between sex, nutritional status, severity of dengue hemorrhagic fever, and immune status in infants with dengue hemorrhagic fever. Am J Trop Med Hyg (2005) 1.34

The crystal structures of Chikungunya and Venezuelan equine encephalitis virus nsP3 macro domains define a conserved adenosine binding pocket. J Virol (2009) 1.32

HLA-A, -B, -C, and -DRB1 allele frequencies in Cuban individuals with antecedents of dengue 2 disease: advantages of the Cuban population for HLA studies of dengue virus infection. Hum Immunol (2007) 1.29

A simple method for molecular detection of Swine-origin and human-origin influenza a virus. Vector Borne Zoonotic Dis (2010) 1.27

Genomics and evolution of Aedes-borne flaviviruses. J Gen Virol (2009) 1.26

Controlling dengue with vaccines in Thailand. PLoS Negl Trop Dis (2012) 1.25

A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates. Vaccine (2006) 1.24

How innate immune mechanisms contribute to antibody-enhanced viral infections. Clin Vaccine Immunol (2010) 1.23

Nonviremic transmission of West Nile virus. Proc Natl Acad Sci U S A (2005) 1.22

The wages of original antigenic sin. Emerg Infect Dis (2010) 1.21

Dengue haemorrhagic fever integral hypothesis: confirming observations, 1987-2007. Trans R Soc Trop Med Hyg (2008) 1.21

Immune response to synthetic peptides of dengue prM protein. Vaccine (2002) 1.19

Mortality following peripheral infection with tick-borne encephalitis virus results from a combination of central nervous system pathology, systemic inflammatory and stress responses. Virology (2009) 1.18

Classical dengue hemorrhagic fever resulting from two dengue infections spaced 20 years or more apart: Havana, Dengue 3 epidemic, 2001-2002. Int J Infect Dis (2005) 1.17

MAC-ELISA and ELISA inhibition methods for detection of antibodies after yellow fever vaccination. J Virol Methods (2003) 1.16

Detection of seroconversion to West Nile virus, Usutu virus and Sindbis virus in UK sentinel chickens. Virol J (2006) 1.16

Taxonomy of the virus family Flaviviridae. Adv Virus Res (2003) 1.14

PCR detection of dengue virus using dried whole blood spotted on filter paper. J Virol Methods (2005) 1.14

Sandfly-borne phleboviruses of Eurasia and Africa: epidemiology, genetic diversity, geographic range, control measures. Antiviral Res (2013) 1.13

Volume replacement in infants with dengue hemorrhagic fever/dengue shock syndrome. Am J Trop Med Hyg (2006) 1.13

Likely correlation between sources of information and acceptability of A/H1N1 swine-origin influenza virus vaccine in Marseille, France. PLoS One (2010) 1.12

CD8+ T-cells mediate immunopathology in tick-borne encephalitis. Virology (2008) 1.12

Novel virus discovery and genome reconstruction from field RNA samples reveals highly divergent viruses in dipteran hosts. PLoS One (2013) 1.10

Dengue: where are we today? Malays J Med Sci (2009) 1.10

Domain III of the envelope protein as a dengue vaccine target. Expert Rev Vaccines (2010) 1.10

Dengue 3 epidemic, Havana, 2001. Emerg Infect Dis (2004) 1.10

Universal primers that amplify RNA from all three flavivirus subgroups. Virol J (2008) 1.09

Mutations in the NS2B and NS3 genes affect mouse neuroinvasiveness of a Western European field strain of tick-borne encephalitis virus. Virology (2008) 1.06

Genomic and antigenic characterization of the newly emerging Chinese duck egg-drop syndrome flavivirus: genomic comparison with Tembusu and Sitiawan viruses. J Gen Virol (2012) 1.06

The potential for West Nile virus to establish outside of its natural range: a consideration of potential mosquito vectors in the United Kingdom. Trans R Soc Trop Med Hyg (2004) 1.05

Understanding the dengue viruses and progress towards their control. Biomed Res Int (2013) 1.02

Immunogenicity and protective efficacy of a recombinant fusion protein containing the domain III of the dengue 1 envelope protein in non-human primates. Antiviral Res (2008) 1.00

Call to action for dengue vaccine failure. Emerg Infect Dis (2013) 1.00

The complexity of antibody-dependent enhancement of dengue virus infection. Viruses (2010) 0.99

Primary and secondary infections of Macaca fascicularis monkeys with Asian and American genotypes of dengue virus 2. Clin Vaccine Immunol (2007) 0.97

Dengue Antibody-Dependent Enhancement: Knowns and Unknowns. Microbiol Spectr (2014) 0.97

EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis. J Clin Invest (2014) 0.97

Dengue vascular permeability syndrome: what, no T cells? Clin Infect Dis (2012) 0.96

Ethnicity and difference in dengue virus-specific memory T cell responses in Cuban individuals. Viral Immunol (2006) 0.95

Tumor necrosis factor-alpha, transforming growth factor-β1, and interleukin-10 gene polymorphisms: implication in protection or susceptibility to dengue hemorrhagic fever. Hum Immunol (2010) 0.94

[Efficacy and safety of a vaccine against human leptospirosis in Cuba]. Rev Panam Salud Publica (2004) 0.94

Recombination and flavivirus vaccines: a commentary. Vaccine (2005) 0.94

Amino acid changes in the recombinant Dengue 3 Envelope domain III determine its antigenicity and immunogenicity in mice. Virus Res (2006) 0.94

Research priorities for neglected infectious diseases in Latin America and the Caribbean region. PLoS Negl Trop Dis (2010) 0.94

Virus evolution during a severe dengue epidemic in Cuba, 1997. Virology (2005) 0.93

Fatal severe dengue and cell death in sickle cell disease during the 2001-2002 Havana dengue epidemic. Int J Infect Dis (2008) 0.93

A novel fusion protein domain III-capsid from dengue-2, in a highly aggregated form, induces a functional immune response and protection in mice. Virology (2009) 0.93

Anamnestic antibody response after viral challenge in monkeys immunized with dengue 2 recombinant fusion proteins. Arch Virol (2008) 0.93

Noncoding RNAs in cancer and cancer stem cells. Chin J Cancer (2013) 0.92

Dengue virus type 3, Cuba, 2000-2002. Emerg Infect Dis (2005) 0.92

An integrated ecosystem approach for sustainable prevention and control of dengue in Central Havana. Int J Occup Environ Health (2007) 0.92

Diagnosis of west nile virus human infections: overview and proposal of diagnostic protocols considering the results of external quality assessment studies. Viruses (2013) 0.91

Long-term memory cellular immune response to dengue virus after a natural primary infection. Int J Infect Dis (2002) 0.91